Transplants for the elderly in myeloma

Slides:

Advertisements

Similar presentations

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis by.

Advertisements

RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society.

1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,

CD4 T cells: fates, functions, and faults by Jinfang Zhu, and William E. Paul Blood Volume 112(5): September 1, 2008 ©2008 by American Society.

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.

Phenotypic and Functional Changes Induced at the Clonal Level in Hematopoietic Stem Cells After 5-Fluorouracil Treatment by Troy D. Randall, and Irving.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

How I treat extramedullary myeloma

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

Alternate designs for conduct and analysis of phase I cancer trials

by Henrik Frederiksen, and Kai Schmidt

by Timothy P. Hughes, and David M. Ross

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

Positioning NK-κB in multiple myeloma

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

BTK inhibition in myeloma: targeting the seed and the soil

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

How I treat elderly patients with myeloma

How to Treat MDS without Stem Cell Transplantation

Nonmyeloablative conditioning for relapsed follicular lymphoma

Darwinian evolution and tiding clones in multiple myeloma

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Functional neutrophils from human ES cells

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.

Deep mining of the RBC proteome

Acute promyelocytic leukemia, microgranular variant

An actuarial GPS for hemophilic longevity

Taking a leaf from the book of oral tolerance

Has the T cell bitten off more than it can chew?

التعلم بالإكتشاف المراجع:

by Sabah Sallah, and Jim Y. Wan

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Stage C or not stage C…? by Claire Dearden Blood

Primary testicular lymphoma

ROCK and Rho(ll) in bone marrow

by Ineke J. M. ten Berge, and René A. W. van Lier

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Blocking VWF platelet binding to treat TTP

Has MRD monitoring superseded other prognostic factors in adult ALL?

Latest lymphoma classification is skin deep

Allogeneic Stem Cell Transplantation in Myelofibrosis

Anergy: the CLL cell limbo

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

Blood and Marrow Transplant Handbook

Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy

Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Mark A. Fiala, Joseph D. Finney, Keith.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Treatment versus Transplant for Challenging Hematologic Disorders

Biology and treatment of Richter syndrome

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary.

In Memoriam: E. Donnall Thomas

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

by Lucy A. Godley, and Akiko Shimamura

by Lapo Alinari, and Kristie A. Blum

Initial treatment of CLL: integrating biology and functional status

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Optimizing therapy for nodal marginal zone lymphoma

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia by Mohamed Bradai, Mohand Tayeb Abad, Serge Pissard, Fatima Lamraoui,

Cold agglutinin disease

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective.

Presentation transcript:

Transplants for the elderly in myeloma by Gareth J. Morgan Blood Volume 122(8):1332-1334 August 22, 2013 ©2013 by American Society of Hematology

The key elements of modern treatment strategies: sequential treatment approach for myeloma. The key elements of modern treatment strategies: sequential treatment approach for myeloma. Ongoing treatment with an induction phase, followed by intensification (transplant), consolidation, and a maintenance phase. Gareth J. Morgan Blood 2013;122:1332-1334 ©2013 by American Society of Hematology